keyword
MENU ▼
Read by QxMD icon Read
search

Denosumab

keyword
https://www.readbyqxmd.com/read/28325144/therapeutic-potential-and-outlook-of-alternative-medicine-for-osteoporosis
#1
Tao Wang, Qian Liu, William Tjhioe, Jinmin Zhao, Aiping Lu, Ge Zhang, Renxiang Tan, Mengyu Zhou, Jiake Xu, Haotian Feng
Osteoporosis, a bone disease resulting in loss of bone density and microstructure quality, is often associated with fragility fractures, and the latter imposes a great burden on the patient and society. Although there are several different treatments available for osteoporosis such as hormone replacement therapy, bisphosphonates, Denosumab, and parathyroid hormone some concern has been raised regarding the inherent side effects of their long term use. It would be of great relevance to search for alternative natural compounds, which could complementarily overcome the limitations of the currently available therapy...
March 21, 2017: Current Drug Targets
https://www.readbyqxmd.com/read/28324746/denosumab-in-advanced-unresectable-giant-cell-tumour-of-bone-gctb-for-how-long
#2
E Palmerini, N S Chawla, S Ferrari, M Sudan, P Picci, E Marchesi, M Piccinni Leopardi, I Syed, K K Sankhala, P Parthasarathy, W E Mendanha, M Pierini, A Paioli, S P Chawla
BACKGROUND: Giant-cell tumours of bone (GCTB) are RANK/RANK-ligand (RANKL) positive, aggressive and progressive osteolytic tumours. Denosumab, a RANKL inhibitor, was FDA-approved for adults and skeletally mature adolescents with unresectable GCTB or when surgical resection is likely to result in severe morbidity. Data on long-term toxicity and activity of denosumab monthly 'GCTB-schedule' (120 mg per 12/year, 1440 mg total dose/year) are lacking. METHODS: Patients with GCTB receiving denosumab, 120 mg on days 1, 8, 15, 29 and every 4 weeks thereafter, from 2006 to 2015 treated in two centres were included...
March 16, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/28321061/effects-of-denosumab-on-bone-metabolic-markers-and-bone-mineral-density-in-patients-treated-with-glucocorticoids
#3
Masato Sawamura, Atsushi Komatsuda, Masaru Togashi, Hideki Wakui, Naoto Takahashi
Objective We performed a prospective study to determine the efficacy and safety of denosumab on bone metabolic indices and bone mineral density (BMD) in 29 patients receiving long-term glucocorticoids (GCs) who had clinical risk factors for fracture. Methods Among these patients, 16 had systemic lupus erythematosus (SLE), 6 RA, 4 other autoimmune diseases, and 3 renal diseases. All patients received donosumab 60 mg at baseline and 6 months. Serum N-terminal cross-linked telopeptide of type I collagen (NTX) and bone-specific alkaline phosphatase (BAP) levels were measured as bone metabolic indices...
2017: Internal Medicine
https://www.readbyqxmd.com/read/28304090/osteoporosis-treatment-efficacy-for-men-a-systematic-review-and-meta-analysis
#4
Smita Nayak, Susan L Greenspan
OBJECTIVES: To evaluate the efficacy of treatment options to reduce osteoporotic fracture risk in men. DESIGN: Systematic review and meta-analysis. SETTING: Randomized clinical trials that evaluated the efficacy of a treatment for osteoporosis or low bone mineral density for adult men and reported fracture outcomes. PARTICIPANTS: Men. MEASUREMENTS: PubMed, Embase, and the Cochrane Library databases were searched for relevant studies...
March 2017: Journal of the American Geriatrics Society
https://www.readbyqxmd.com/read/28303448/parathyroid-hormone-and-parathyroid-hormone-related-protein-analogs-in-osteoporosis-therapy
#5
REVIEW
Benjamin Z Leder
PURPOSE OF REVIEW: The purpose is to review the efficacy and optimal use of parathyroid hormone and parathyroid hormone-related protein analogs in osteoporosis treatment. RECENT FINDINGS: The parathyroid hormone analog teriparatide, a potent stimulator of bone remodeling, increases hip and spine bone mineral density and reduces the risk of vertebral and non-vertebral fractures in postmenopausal osteoporotic women. The parathyroid hormone-related protein analog, abaloparatide, also reduces fracture incidence but has pharmacological effects that differ from teriparatide, particularly in cortical bone...
March 16, 2017: Current Osteoporosis Reports
https://www.readbyqxmd.com/read/28290756/denosumab-and-surgery-for-the-treatment-of-perthes-disease-in-a-9-year-old-boy-favorable-course-documented-by-comprehensive-imaging-a-case-report
#6
A Ludwig Meiss, Florian Barvencik, Kornelia Babin, Gerald Eggers-Stroeder
No abstract text is available yet for this article.
March 14, 2017: Acta Orthopaedica
https://www.readbyqxmd.com/read/28287044/no-effect-of-teriparatide-on-migration-in-total-knee-replacement
#7
Håkan Ledin, Lars Good, Torsten Johansson, Per Aspenberg
Background and purpose - Aseptic loosening is a main cause of late revision in total knee replacement (TKR). Teriparatide, a recombinant parathyroid hormone (PTH), stimulates osteoblasts and has been suggested to improve cancellous bone healing in humans. This might also be relevant for prosthesis fixation. We used radiostereometric analysis (RSA) to investigate whether teriparatide influences prosthesis fixation. Early migration as measured by RSA can predict future loosening. Patients and methods - In a randomized controlled trial with blind evaluation, 50 patients with osteoarthritis of the knee were allocated to a teriparatide treatment group (Forsteo, 20 μg daily for 2 months postoperatively) or to an untreated control group...
March 13, 2017: Acta Orthopaedica
https://www.readbyqxmd.com/read/28287004/denosumab-reduces-early-migration-in-total-knee-replacement
#8
Håkan Ledin, Lars Good, Per Aspenberg
Background and purpose - Aseptic loosening is a main cause of late revision in total knee replacement (TKR). Migration of implants as measured by radiostereometric analysis (RSA) can predict future loosening. This migration is associated with bone resorption. Denosumab is a human monoclonal antibody that binds to receptors on osteoclast precursors and osteoclasts. This prevents osteoclast formation, resulting in less bone resorption in cortical and trabecular bone. We investigated whether denosumab can reduce migration of TKR, as measured with RSA...
March 13, 2017: Acta Orthopaedica
https://www.readbyqxmd.com/read/28286773/the-strategy-to-prevent-and-regress-the-vascular-calcification-in-dialysis-patients
#9
REVIEW
Nai-Ching Chen, Chih-Yang Hsu, Chien-Liang Chen
The high prevalence of arterial calcification in end-stage renal disease (ESRD) is far beyond the explanation by common cardiovascular risk factors such as aging, diabetes, hypertension, and dyslipidemia. The finding relies on the fact that vascular and valvular calcifications are predictors of cardiovascular diseases and mortality in persons with chronic renal failure. In addition to traditional cardiovascular risk factors such as diabetes mellitus and blood pressure control, other ESRD-related risks such as phosphate retention, excess calcium, and prolonged dialysis time also contribute to the development of vascular calcification...
2017: BioMed Research International
https://www.readbyqxmd.com/read/28286299/importance-of-prompt-antiresorptive-therapy-in-postmenopausal-women-discontinuing-teriparatide-or-denosumab-the-denosumab-and-teriparatide-follow-up-study-data-follow-up
#10
Benjamin Z Leder, Joy N Tsai, Linda A Jiang, Hang Lee
When teriparatide and denosumab are discontinued, bone mineral density (BMD) abruptly decreases. To compare rates of bone loss in postmenopausal women who discontinue denosumab or teriparatide and receive no additional prescription osteoporosis medications to women who discontinue these drugs followed by prompt antiresorptive therapy, we asked women concluding the Denosumab and Teriparatide Administration (DATA) study and its extension, DATA-Switch, to return for BMD measurements 1-2years after study completion...
March 9, 2017: Bone
https://www.readbyqxmd.com/read/28286298/the-effects-of-parathyroid-hormone-peptides-on-the-peripheral-skeleton-of-postmenopausal-women-a-systematic-review
#11
REVIEW
Louis M Metcalf, Terry J Aspray, Eugene V McCloskey
Given current developments in anabolic therapy for bone, we wished to document the effects of the only currently available anabolic therapy, parathyroid hormone (PTH) peptides, on the peripheral skeleton of postmenopausal women. We undertook a systematic review of English articles using MEDLINE, Scopus and the Cochrane Controlled Trials Register (final update 28th March 2016). Additional studies were identified through searches of bibliographies. Studies included those comparing PTH peptides with placebo, with anti-osteoporotic treatments and in combination therapies...
March 9, 2017: Bone
https://www.readbyqxmd.com/read/28285639/denosumab-for-the-treatment-of-adult-multisystem-langerhans-cell-histiocytosis
#12
Polyzois Makras, Marina Tsoli, Athanasios D Anastasilakis, Maria Thanou, Gregory Kaltsas
PURPOSE: An etiological treatment is currently lacking for Langerhans Cell Histiocytosis (LCH). Receptor activator of nuclear factor κB ligand (RANKL) appears to play a central role in the lesional immunological process inducing compensatory osteoprotegerin (OPG) activation. In a preliminary study we aimed to evaluate for the first time the use of denosumab, a RANKL inhibitor, as a targeted treatment strategy in LCH in order to support and enhance endogenous OPG action in order to control or alter the lesional immunological process...
April 2017: Metabolism: Clinical and Experimental
https://www.readbyqxmd.com/read/28283537/increased-osteoclastogenesis-in-patients-with-vertebral-fractures-following-discontinuation-of-denosumab-treatment
#13
Athanasios D Anastasilakis, Maria P Yavropoulou, Polyzois Makras, Grigorios T Sakellariou, Foteini Papadopoulou, Spyridon Gerou, Socrates Papapoulos
OBJECTIVE: To test the hypothesis that rebound of bone remodeling is responsible for clinical vertebral fractures reported in a few patients with osteoporosis after cessation of denosumab treatment. DESIGN: In this case-control study we compared clinical and biochemical characteristics of postmenopausal women with clinical vertebral fractures 8 to 16 months after the last injection of denosumab (Dmab/Fx+, n=5) with those of treatment-naïve women with such fractures (Fx+, n=5)...
March 10, 2017: European Journal of Endocrinology
https://www.readbyqxmd.com/read/28281587/mronj-risk-reduction-pathway-360-degree-survey
#14
A Muthukrishnan, S Al-Ismail, G Bertelli, P Browne
Introduction Bisphosphonates and denosumab reduce the risk of skeletal events in some malignancies (for example, breast, myeloma). These drugs carry a significant risk of a difficult-to-manage side effect of medication related osteonecrosis of the jaw (MRONJ). Preventive dental screening and treatment reduces the incidence of MRONJ. A managed clinical network (MCN) has been used to provide a MRONJ risk reduction pathway. A 360 degree survey was undertaken to assess the effectiveness of the pathway.Aim The aim of the 360 degree survey was to evaluate if this preventive pathway fulfilled its aims based on patient and stakeholder responses...
March 10, 2017: British Dental Journal
https://www.readbyqxmd.com/read/28277603/safety-observations-with-three-years-of-denosumab-exposure-comparison-between-subjects-who-received-denosumab-during-the-randomized-freedom-trial-and-subjects-who-crossed-over-to-denosumab-during-the-freedom-extension
#15
N B Watts, J P Brown, S Papapoulos, E M Lewiecki, D L Kendler, P Dakin, R B Wagman, A Wang, N S Daizadeh, S Smith, H G Bone
Denosumab is a fully human monoclonal antibody against RANKL that decreases osteoclast formation, function and survival, and is approved for the treatment of postmenopausal women with osteoporosis at increased or high risk for fracture, among other indications. During the pivotal 3-year fracture trial FREEDOM, denosumab 60 mg subcutaneously every 6 months significantly reduced new vertebral (68%), hip (40%), and nonvertebral (20%) fractures; increased bone mineral density (BMD); and reduced bone turnover markers compared with placebo in postmenopausal women with osteoporosis...
March 9, 2017: Journal of Bone and Mineral Research: the Official Journal of the American Society for Bone and Mineral Research
https://www.readbyqxmd.com/read/28275116/retrospective-review-of-atypical-femoral-fracture-in-metastatic-bone-disease-patients-receiving-denosumab-therapy
#16
Samantha Peiling Yang, Tae Won B Kim, Patrick J Boland, Azeez Farooki
BACKGROUND: Denosumab therapy is used to reduce skeletal-related events in metastatic bone disease (MBD). There have been reports of atypical femoral fracture (AFF) in osteoporotic patients treated with denosumab but none in the context of higher dose and more frequent denosumab therapy for MBD. The goal of this study was to assess the incidence of AFF in MBD. PATIENTS AND METHODS: We conducted a retrospective review of 253 patients who received a minimum of 12 doses of denosumab at 120 mg each for MBD...
March 8, 2017: Oncologist
https://www.readbyqxmd.com/read/28255336/bone-modeling-and-remodeling-potential-as-therapeutic-targets-for-the-treatment-of-osteoporosis
#17
REVIEW
Bente Langdahl, Serge Ferrari, David W Dempster
The adult skeleton is renewed by remodeling throughout life. Bone remodeling is a process where osteoclasts and osteoblasts work sequentially in the same bone remodeling unit. After the attainment of peak bone mass, bone remodeling is balanced and bone mass is stable for one or two decades until age-related bone loss begins. Age-related bone loss is caused by increases in resorptive activity and reduced bone formation. The relative importance of cortical remodeling increases with age as cancellous bone is lost and remodeling activity in both compartments increases...
December 2016: Therapeutic Advances in Musculoskeletal Disease
https://www.readbyqxmd.com/read/28250248/comparative-effects-of-denosumab-or-bisphosphonate-treatment-on-bone-mineral-density-and-calcium-metabolism-in-postmenopausal-women
#18
A Augoulea, E Tsakonas, I Triantafyllopoulos, D Rizos, E Armeni, N Tsoltos, S Tournis, E Deligeoroglou, A Antoniou, I Lambrinoudaki
OBJECTIVES: To clarify potential differences between denosumab (DNS) and bisphosphonates (BIS) in terms of bone density and bone metabolism, in a sample of postmenopausal women. METHODS: A total of 113 postmenopausal women aged 53-66 years were treated with either DNS or BIS for 12 months. Bone densitometry and laboratory tests were compared between baseline and follow-up. RESULTS: Femoral neck BMD increased in both treatment-arms (FN-BMD, DNS: 0...
March 1, 2017: Journal of Musculoskeletal & Neuronal Interactions
https://www.readbyqxmd.com/read/28247363/atypical-fracture-of-the-sternum-after-long-term-alendronate-plus-cholecalciferol-treatment-a-case-report
#19
Luis H Martín Arias, Pilar García Ortega, María Sáinz Gil, Ester Navarro García, Carlos Treceño Lobato, Virginia Delgado Armas
A 55-year-old woman developed an atraumatic sternum fracture during treatment with alendronate for osteoporosis. The woman received alendronate 70 mg in combination with cholecalciferol 5600 IU once weekly, as well as nonsteroidal anti-inflammatory drugs. After 4 years of treatment, following a dorsal flexion with no direct thoracic trauma, the patient suffered a fracture of the sternum, with an X-ray revealing sternal body fracture. This fracture was seen to be transverse, noncomminuted and without displacement...
December 2017: Drug Safety—Case Reports
https://www.readbyqxmd.com/read/28243883/two-year-persistence-and-compliance-with-osteoporosis-therapies-among-postmenopausal-women-in-a-commercially-insured-population-in-the-united-states
#20
Emily Durden, Lionel Pinto, Lorena Lopez-Gonzalez, Paul Juneau, Richard Barron
This retrospective, observational study assessed 2-year persistence and compliance by treatment, route of administration, and dosing frequency in postmenopausal women initiating a new osteoporosis therapy. Two-year persistence and compliance rates were higher in women receiving injectables compared with oral agents. PURPOSE: This study extends previous studies limited to 1-year follow-up by examining persistence with osteoporosis therapies over a 2-year period and compares short- and long-term trends in persistence and compliance among postmenopausal women with commercial or Medicare supplemental insurance in the USA...
December 2017: Archives of Osteoporosis
keyword
keyword
8329
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"